Blockbuster in the balance: Celgene's Reblozyl faces FDA committee for myelodysplastic syndromes
admin 3rd December 2019 Uncategorised 0In its final days as an independent company, Celgene scored a win last month with the FDA’s approval of rare blood disease med Reblozyl—a potential blockbuster in some analysts’ eyes. Now, the FDA wants a closer look at Reblozyl as a treatment for a group of rare blood cancers.
More: Blockbuster in the balance: Celgene's Reblozyl faces FDA committee for myelodysplastic syndromes
Source: fierce